CN103330684A - Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule - Google Patents
Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule Download PDFInfo
- Publication number
- CN103330684A CN103330684A CN2013102764710A CN201310276471A CN103330684A CN 103330684 A CN103330684 A CN 103330684A CN 2013102764710 A CN2013102764710 A CN 2013102764710A CN 201310276471 A CN201310276471 A CN 201310276471A CN 103330684 A CN103330684 A CN 103330684A
- Authority
- CN
- China
- Prior art keywords
- diammonium glycyrrhizinate
- lipid complex
- preparation
- diammonium
- glycyrrhizinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 64
- -1 diammonium glycyrrhizinate lipid compound Chemical class 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 54
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims abstract description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 27
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 19
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 16
- 238000010992 reflux Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 6
- 150000002632 lipids Chemical class 0.000 claims abstract 3
- 238000001816 cooling Methods 0.000 claims abstract 2
- 238000005303 weighing Methods 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000796 flavoring agent Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 235000019634 flavors Nutrition 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000005550 wet granulation Methods 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 4
- 238000000746 purification Methods 0.000 claims 3
- 238000013019 agitation Methods 0.000 claims 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 241000207199 Citrus Species 0.000 claims 1
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 235000011477 liquorice Nutrition 0.000 claims 1
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 150000007984 tetrahydrofuranes Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 239000002479 lipoplex Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- 230000003908 liver function Effects 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 21
- 239000013078 crystal Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 13
- 229940083466 soybean lecithin Drugs 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000003760 magnetic stirring Methods 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002662 enteric coated tablet Substances 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 239000007968 orange flavor Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229960002668 sodium chloride Drugs 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及甘草酸二铵脂质复合物泡腾颗粒的制备方法。目的是提供的方法应能有效提升药物吸收效果和生物利用度,以达到保护肝细胞膜和改善肝功能的效果,还具有服用方便的特点。技术方案是:甘草酸二铵脂质复合物泡腾颗粒的制备方法,按照以下步骤进行:1)制取甘草酸二铵脂质复合物混合物;2)通过湿法制粒将甘草酸二铵脂质复合物混合物制成甘草酸二铵脂质复合物泡腾颗粒。所述甘草酸二铵脂质复合物的制备方法为:1)制取大豆磷脂四氢呋喃溶液;2)称取甘草酸二铵提纯物,进行回流溶解,当溶液澄明后取出静置;3)制取甘草酸二铵脂质复合物。所述碳酸氢钠包合物的制备方法为:1)进行包合,包合均匀后冷却至室温;2)得到碳酸氢钠包合物。The invention relates to a preparation method of diammonium glycyrrhizinate lipid complex effervescent granules. The purpose is that the method provided should be able to effectively improve the drug absorption effect and bioavailability, so as to achieve the effect of protecting liver cell membrane and improving liver function, and also has the characteristics of convenient administration. The technical solution is: the preparation method of diammonium glycyrrhizinate lipid complex effervescent granules is carried out according to the following steps: 1) preparing the diammonium glycyrrhizinate lipid complex mixture; 2) making diammonium glycyrrhizinate lipid Diammonium glycyrrhizinate lipoplex effervescent granules were made from the lipid complex mixture. The preparation method of the diammonium glycyrrhizinate lipid complex is as follows: 1) preparing soybean phospholipid tetrahydrofuran solution; 2) weighing the purified diammonium glycyrrhizinate, refluxing and dissolving it, and taking it out and standing when the solution is clear; 3) preparing Take diammonium glycyrrhizinate lipoplex. The preparation method of the sodium bicarbonate clathrate comprises: 1) carrying out clathrate, cooling to room temperature after clathrate is uniform; 2) obtaining the clathrate of sodium bicarbonate.
Description
技术领域technical field
本发明涉及一种药物的制备方法,具体是一种甘草酸二铵脂质复合物泡腾颗粒的制备方法。The invention relates to a preparation method of medicine, in particular to a preparation method of diammonium glycyrrhizinate lipid complex effervescent granules.
背景技术Background technique
甘草酸二铵(Diammonium Glycyrrhizinate,DG)是治疗肝病的有效药物,它能显著降低血清谷丙转氨酶和谷草转氨酶,并能保护肝细胞膜及改善肝功能,适用于伴有谷丙转氨酶升高的慢性迁延性肝炎及慢性活动性肝炎。Diammonium Glycyrrhizinate (DG) is an effective drug for the treatment of liver diseases. It can significantly reduce serum alanine aminotransferase and aspartate aminotransferase, protect liver cell membranes and improve liver function. It is suitable for chronic diseases with elevated alanine aminotransferase. Persistent hepatitis and chronic active hepatitis.
现在市售的DG制剂主要包括肠溶片、肠溶胶囊和胶囊剂(三者的生物利用度无显著性差异并具有生物等效性),通过口服时主要的吸收部位依次为胃和小肠,如果药物能在胃内快速溶解并且长时间滞留,药物的吸收效果就越好,生物利用度也越高。但DG是一种弱酸性药物,其理化性质决定了易溶于水而不易溶于酸性溶液,因此胶囊剂在胃中溶解缓慢且溶解不完全,肠溶片和肠溶胶囊也存在崩解缓慢的问题。The DG preparations currently on the market mainly include enteric-coated tablets, enteric-coated capsules and capsules (there is no significant difference in bioavailability among the three and are bioequivalent). If the drug dissolves quickly and stays in the stomach for a long time, the better the absorption effect of the drug and the higher the bioavailability. However, DG is a weakly acidic drug, and its physical and chemical properties determine that it is easily soluble in water but not easily soluble in acidic solutions. Therefore, the capsule dissolves slowly and incompletely in the stomach, and enteric-coated tablets and enteric-coated capsules also have slow disintegration. The problem.
因此,在目前的DG制剂中,肠溶片、肠溶胶囊和胶囊剂在人体内的吸收效果较差,生物利用度较低,保肝降酶效果不是很理想(与其注射剂相比),同时儿童和老人等服药困难人员也较难服用,非常不便。Therefore, in the current DG preparations, enteric-coated tablets, enteric-coated capsules and capsules have poor absorption in the human body, low bioavailability, and the effect of protecting the liver and reducing enzymes is not very satisfactory (compared with its injections), and at the same time People who have difficulty taking medicine such as children and the elderly are also more difficult to take, which is very inconvenient.
发明内容Contents of the invention
本发明的目的是克服上述背景技术中的不足,提供一种甘草酸二铵脂质复合物泡腾颗粒的制备方法,该方法应能有效提升药物吸收效果和生物利用度,以达到保护肝细胞膜和改善肝功能的效果,并且还具有服用方便的特点。The purpose of the present invention is to overcome the deficiencies in the above-mentioned background technology and provide a preparation method of diammonium glycyrrhizinate lipid complex effervescent granules, which should be able to effectively improve the drug absorption effect and bioavailability, so as to protect the liver cell membrane And the effect of improving liver function, and also has the characteristics of taking convenience.
本发明的技术方案是:甘草酸二铵脂质复合物泡腾颗粒的制备方法,按照以下步骤进行:Technical scheme of the present invention is: the preparation method of diammonium glycyrrhizinate lipoplex effervescent granule, carry out according to the following steps:
1)取甘草酸二铵脂质复合物30-35份、抗坏血酸12-18份、填充剂126-132份、枸橼酸30-35份、碳酸氢钠包合物50-55份以及氯化钠28-32份,均匀混合后形成甘草酸二铵脂质复合物混合物;1) Take 30-35 parts of diammonium glycyrrhizinate lipid complex, 12-18 parts of ascorbic acid, 126-132 parts of filler, 30-35 parts of citric acid, 50-55 parts of sodium bicarbonate clathrate and chloride 28-32 parts of sodium, uniformly mixed to form diammonium glycyrrhizinate lipid complex mixture;
2)通过湿法制粒将甘草酸二铵脂质复合物混合物制成甘草酸二铵脂质复合物泡腾颗粒。2) Diammonium glycyrrhizinate lipoplex mixture was made into effervescent granules of diammonium glycyrrhizinate lipoplex by wet granulation.
所述甘草酸二铵脂质复合物的制备方法为:The preparation method of the diammonium glycyrrhizinate lipid complex is:
1)在容器中放入8-12份大豆磷脂和500份四氢呋喃,然后在70±4℃的水浴中通过磁力搅拌进行回流溶解,得到大豆磷脂四氢呋喃溶液;1) Put 8-12 parts of soybean lecithin and 500 parts of tetrahydrofuran into the container, and then reflux and dissolve in a water bath at 70±4°C by magnetic stirring to obtain soybean lecithin tetrahydrofuran solution;
2)称取8-12份甘草酸二铵提纯物,然后倒入冷却后的大豆磷脂四氢呋喃溶液中,轻轻摇动后在70±4℃的水浴中通过磁力搅拌2-4h以上进行回流溶解,当溶液澄明后取出静置;2) Weigh 8-12 parts of purified diammonium glycyrrhizinate, then pour it into the cooled soybean lecithin tetrahydrofuran solution, shake it gently, and then reflux and dissolve it in a water bath at 70±4°C by magnetic stirring for more than 2-4h. When the solution is clear, take it out and let it stand;
3)将上述溶液倾出上清液至另一容器中,旋转蒸发直至无四氢呋喃味,然后研细并过筛,得到含量为45-48%的甘草酸二铵脂质复合物。3) Pour the above solution and pour the supernatant into another container, rotatory evaporate until there is no tetrahydrofuran smell, then grind and sieve to obtain diammonium glycyrrhizinate lipoplex with a content of 45-48%.
所述碳酸氢钠包合物的制备方法为:The preparation method of described sodium bicarbonate clathrate is:
1)加热熔融一定量的聚乙二醇,然后取等量的碳酸氢钠进行搅拌,并向碳酸氢钠中缓慢加入熔融的聚乙二醇进行包合,包合均匀后冷却至室温;1) Heat and melt a certain amount of polyethylene glycol, then take an equal amount of sodium bicarbonate for stirring, and slowly add molten polyethylene glycol to the sodium bicarbonate for clathrate, clathrate evenly and cool to room temperature;
2)将上述包合物研细后并过筛,得到碳酸氢钠包合物。2) Grinding and sieving the above clathrate to obtain the clathrate of sodium bicarbonate.
所述填充剂为木糖醇或蔗糖或葡糖糖或果糖或甘露醇。The filler is xylitol or sucrose or glucose or fructose or mannitol.
所述填充剂中添加有香橙味香精或桔子味香精或草莓味香精或蜜桃味香精。The filling agent is added with orange flavor essence or orange flavor essence or strawberry flavor essence or peach flavor essence.
所述填充剂中添加香精的方法为:The method of adding essence in the described filler is:
1)取一定量的填充剂过筛,并与适量的香精混合后制成颗粒;1) Take a certain amount of filler, sieve it, and mix it with an appropriate amount of essence to make granules;
2)将上述颗粒过筛,然后在40±3℃以上的环境中干燥2h以上;2) Sieve the above granules, and then dry them in an environment above 40±3°C for more than 2 hours;
3)将上述颗粒研细后过筛。3) Grind the above granules finely and sieve.
所述湿法制粒为:Described wet granulation is:
1)将甘草酸二铵脂质复合物混合物加入无水乙醇中制成软材,然后过筛制成湿颗粒,并在40±3℃以上的环境中干燥2h以上;1) Add the diammonium glycyrrhizinate lipid complex mixture into absolute ethanol to make a soft material, then sieve it to make wet granules, and dry it in an environment above 40±3°C for more than 2 hours;
2)将上述颗粒过筛,然后加入6份微晶纤维素和0.15份硬脂酸镁后混合均匀,并在40±3℃的真空环境下干燥2-3h;2) Sieve the above granules, then add 6 parts of microcrystalline cellulose and 0.15 parts of magnesium stearate, mix well, and dry in a vacuum environment at 40±3°C for 2-3 hours;
3)将上述颗粒过筛,得到甘草酸二铵脂质复合物泡腾颗粒。3) Sieve the above granules to obtain diammonium glycyrrhizinate lipid complex effervescent granules.
所述甘草酸二铵提纯物的制备方法为:The preparation method of described diammonium glycyrrhizinate extract is:
1)向容器中加入100份甘草酸二铵和700-900份乙醇水溶液,并在100±5℃的水浴中加热至溶解状态;1) Add 100 parts of diammonium glycyrrhizinate and 700-900 parts of ethanol aqueous solution into the container, and heat in a water bath at 100±5°C until dissolved;
2)将上述溶液静置片刻,然后倾取上清液至另一容器中冷却静置10-14h,通过抽滤得到结晶体;2) Let the above solution stand for a while, then pour the supernatant into another container to cool and stand for 10-14h, and obtain crystals by suction filtration;
3)向容器中加入上述结晶体和500-700份乙醇水溶液,在100±5℃的水浴加热至溶解状态;3) Add the above crystals and 500-700 parts of ethanol aqueous solution into the container, and heat in a water bath at 100±5°C until dissolved;
4)重复步骤2),然后将结晶体晾至无乙醇味状态;4) Repeat step 2), and then dry the crystals to a state without ethanol smell;
5)将上述结晶体在55℃以上的环境中干燥24h以上,得到含量为97.3%的甘草酸二铵提纯物。5) Dry the above-mentioned crystals in an environment above 55°C for more than 24 hours to obtain a purified product of diammonium glycyrrhizinate with a content of 97.3%.
本发明的有益效果是:The beneficial effects of the present invention are:
本发明通过将甘草酸二铵制成泡腾颗粒,泡腾颗粒将以溶液形式在体外溶解(没有在体内的溶解过程),服用后不仅可以显著提升药物吸收效果和生物利用度(血药浓度和肝组织浓度分别约为甘草酸二铵胶囊的2倍和26倍),达到保护肝细胞膜和改善肝功能的效果,对于肝部的康复具有积极意义;同时该泡腾颗粒的服用非常方便,较为适合儿童和老人等服药困难人员使用。In the present invention, diammonium glycyrrhizinate is made into effervescent granules, and the effervescent granules will be dissolved in vitro in the form of a solution (there is no dissolution process in the body), which can not only significantly improve the drug absorption effect and bioavailability (blood drug concentration) and liver tissue concentrations are about 2 times and 26 times that of diammonium glycyrrhizinate capsules respectively), which can protect the liver cell membrane and improve liver function, which is of positive significance for the recovery of the liver; at the same time, the effervescent granules are very convenient to take, It is more suitable for children and the elderly who have difficulties in taking medicine.
具体实施方式Detailed ways
以下将对甘草酸二铵脂质复合物泡腾颗粒的制备方法作进一步说明,但是本发明并不局限于以下实施例。The preparation method of diammonium glycyrrhizinate lipid complex effervescent granules will be further described below, but the present invention is not limited to the following examples.
实施例一:Embodiment one:
第一步、原料的预处理:The first step, pretreatment of raw materials:
1、将甘草酸二铵制成甘草酸二铵脂质复合物;1, diammonium glycyrrhizinate is made into diammonium glycyrrhizinate lipid complex;
1)将甘草酸二铵制成甘草酸二铵提纯物:1) Diammonium glycyrrhizinate is made into diammonium glycyrrhizinate extract:
①向容器中加入100份甘草酸二铵和700份乙醇水溶液(纯度为80-85%),并在95℃的水浴中加热至溶解状态;①Add 100 parts of diammonium glycyrrhizinate and 700 parts of ethanol aqueous solution (80-85% purity) into the container, and heat it in a water bath at 95°C until it dissolves;
②将上述溶液静置片刻,然后倾取上清液至另一容器中冷却静置10h,通过抽滤得到结晶体;②Let the above solution stand for a while, then pour the supernatant into another container to cool and let it stand for 10 hours, and obtain crystals by suction filtration;
③向容器中加入上述结晶体和500份乙醇水溶液(纯度为80-85%),在95℃的水浴加热至溶解状态;③Add the above crystals and 500 parts of ethanol aqueous solution (80-85% purity) into the container, and heat in a water bath at 95°C until dissolved;
④重复步骤②,然后将结晶体晾至无乙醇味状态;④Repeat step ②, and then dry the crystals to a state without ethanol smell;
⑤将上述结晶体在55℃以上的环境中干燥24h以上,得到含量为97.3%的甘草酸二铵提纯物。⑤ Dry the above-mentioned crystals in an environment above 55°C for more than 24 hours to obtain a purified diammonium glycyrrhizinate with a content of 97.3%.
2)将甘草酸二铵提纯物制成甘草酸二铵脂质复合物:2) Make diammonium glycyrrhizinate lipid complex from diammonium glycyrrhizinate extract:
①在容器中放入8份大豆磷脂和500份四氢呋喃,然后在66℃的水浴中通过磁力搅拌进行回流溶解,得到大豆磷脂四氢呋喃溶液;①Put 8 parts of soybean lecithin and 500 parts of tetrahydrofuran into the container, and then reflux and dissolve in a water bath at 66°C by magnetic stirring to obtain a solution of soybean lecithin in tetrahydrofuran;
②称取8份甘草酸二铵提纯物,然后倒入冷却后的大豆磷脂四氢呋喃溶液中,轻轻摇动后在66℃的水浴中通过磁力搅拌2h以上进行回流溶解,当溶液澄明后取出静置;② Weigh 8 parts of the purified diammonium glycyrrhizinate, then pour it into the cooled soybean phospholipid tetrahydrofuran solution, shake it gently, and then reflux and dissolve it in a water bath at 66°C by magnetic stirring for more than 2 hours. When the solution is clear, take it out and let it stand ;
③将上述溶液倾出上清液至另一容器中,旋转蒸发直至无四氢呋喃味,然后研细并过80目筛,得到含量为45-48%的甘草酸二铵脂质复合物。③Pour the above solution into another container and pour the supernatant into another container, and evaporate until there is no tetrahydrofuran smell, then grind it finely and pass it through an 80-mesh sieve to obtain diammonium glycyrrhizinate lipid complex with a content of 45-48%.
2、用聚二乙醇包合碳酸氢钠:2. Inclusion of sodium bicarbonate with polyethylene glycol:
1)加热熔融一定量的聚乙二醇,然后取等量的碳酸氢钠进行搅拌,并向碳酸氢钠中缓慢加入熔融的聚乙二醇进行包合,包合均匀后冷却至室温;1) Heat and melt a certain amount of polyethylene glycol, then take an equal amount of sodium bicarbonate for stirring, and slowly add molten polyethylene glycol to the sodium bicarbonate for clathrate, clathrate evenly and cool to room temperature;
2)将上述包合物研细后并过80目筛,得到碳酸氢钠包合物。2) Grind the above clathrate and pass through an 80-mesh sieve to obtain the clathrate of sodium bicarbonate.
3、填充剂中添加香精:3. Add flavor to filler:
1)取一定量的木糖醇过80目筛,并与适量的香橙味香精混合后制成颗粒;1) Take a certain amount of xylitol and pass it through an 80-mesh sieve, and mix it with an appropriate amount of orange flavor essence to make granules;
2)将上述颗粒过80目筛,然后在37℃以上的环境中干燥2h以上;2) Pass the above granules through an 80-mesh sieve, and then dry them in an environment above 37°C for more than 2 hours;
3)将上述颗粒研细后过80目筛。3) Grind the above particles finely and pass through an 80-mesh sieve.
4、将微晶纤维素、硬脂酸镁、抗坏血酸、枸橼酸、氯化钠过80目筛。4. Pass microcrystalline cellulose, magnesium stearate, ascorbic acid, citric acid and sodium chloride through an 80-mesh sieve.
第二步、取甘草酸二铵脂质复合物30份、抗坏血酸12份、矫味剂126份、枸橼酸30份、碳酸氢钠包合物50份以及氯化钠28份,均匀混合形成甘草酸二铵脂质复合物混合物;The second step, take 30 parts of diammonium glycyrrhizinate lipid complex, 12 parts of ascorbic acid, 126 parts of flavoring agent, 30 parts of citric acid, 50 parts of sodium bicarbonate clathrate and 28 parts of sodium chloride, and mix evenly to form Diammonium Glycyrrhizinate Lipid Complex Mixture;
第三步、通过湿法制粒将甘草酸二铵脂质复合物混合物制成甘草酸二铵脂质复合物泡腾颗粒;湿法制粒分以下步骤:In the third step, the diammonium glycyrrhizinate lipid complex mixture is made into diammonium glycyrrhizinate lipid complex effervescent granules by wet granulation; the wet granulation is divided into the following steps:
1、将甘草酸二铵脂质复合物混合物加入无水乙醇中制成软材,然后过16目筛制成湿颗粒,并在37℃以上的环境中干燥2h以上;1. Add diammonium glycyrrhizinate lipid complex mixture into absolute ethanol to make a soft material, then pass through a 16-mesh sieve to make wet granules, and dry in an environment above 37°C for more than 2 hours;
2、将上述颗粒过16目筛,然后加入6份微晶纤维素和0.15份硬脂酸镁后混合均匀,并在37℃的真空环境下干燥2h;2. Pass the above granules through a 16-mesh sieve, then add 6 parts of microcrystalline cellulose and 0.15 parts of magnesium stearate, mix well, and dry at 37°C for 2 hours in a vacuum environment;
3、将上述颗粒过16目筛,得到甘草酸二铵脂质复合物泡腾颗粒。3. Pass the above granules through a 16-mesh sieve to obtain diammonium glycyrrhizinate lipid complex effervescent granules.
实施例二:Embodiment two:
第一步、原料的预处理:The first step, pretreatment of raw materials:
1、将甘草酸二铵制成甘草酸二铵脂质复合物;1, diammonium glycyrrhizinate is made into diammonium glycyrrhizinate lipid complex;
1)将甘草酸二铵制成甘草酸二铵提纯物:1) Diammonium glycyrrhizinate is made into diammonium glycyrrhizinate extract:
①向容器中加入100份甘草酸二铵和800份乙醇水溶液(纯度为80-85%),并在100℃的水浴中加热至溶解状态;① Add 100 parts of diammonium glycyrrhizinate and 800 parts of ethanol aqueous solution (purity 80-85%) into the container, and heat it in a water bath at 100°C until it dissolves;
②将上述溶液静置片刻,然后倾取上清液至另一容器中冷却静置12h,通过抽滤得到结晶体;②Let the above solution stand for a while, then pour the supernatant into another container to cool and stand for 12 hours, and obtain crystals by suction filtration;
③向容器中加入上述结晶体和600份乙醇水溶液(纯度为80-85%),在100℃的水浴加热至溶解状态;③ Add the above crystals and 600 parts of ethanol aqueous solution (80-85% purity) into the container, and heat in a water bath at 100°C until dissolved;
④重复步骤②,然后将结晶体晾至无乙醇味状态;④Repeat step ②, and then dry the crystals to a state without ethanol smell;
⑤将上述结晶体在55℃以上的环境中干燥24h以上,得到含量为97.3%的甘草酸二铵提纯物。⑤ Dry the above-mentioned crystals in an environment above 55°C for more than 24 hours to obtain a purified diammonium glycyrrhizinate with a content of 97.3%.
2)将甘草酸二铵提纯物制成甘草酸二铵脂质复合物:2) Make diammonium glycyrrhizinate lipid complex from diammonium glycyrrhizinate extract:
①在容器中放入10份大豆磷脂和500份四氢呋喃,然后在70℃的水浴中通过磁力搅拌进行回流溶解,得到大豆磷脂四氢呋喃溶液;① Put 10 parts of soybean lecithin and 500 parts of tetrahydrofuran in a container, and then reflux and dissolve in a water bath at 70°C by magnetic stirring to obtain a solution of soybean lecithin in tetrahydrofuran;
②称取10份甘草酸二铵提纯物,然后倒入冷却后的大豆磷脂四氢呋喃溶液中,轻轻摇动后在70℃的水浴中通过磁力搅拌3h以上进行回流溶解,当溶液澄明后取出静置;② Weigh 10 parts of the purified diammonium glycyrrhizinate, then pour it into the cooled soybean phospholipid tetrahydrofuran solution, shake it gently, and then reflux and dissolve it in a water bath at 70°C by magnetic stirring for more than 3 hours. When the solution is clear, take it out and let it stand ;
③将上述溶液倾出上清液至另一容器中,旋转蒸发直至无四氢呋喃味,然后研细并过80目筛,得到含量为45-48%的甘草酸二铵脂质复合物。③Pour the above solution into another container and pour the supernatant into another container, and evaporate until there is no tetrahydrofuran smell, then grind it finely and pass it through an 80-mesh sieve to obtain diammonium glycyrrhizinate lipid complex with a content of 45-48%.
2、用聚二乙醇包合碳酸氢钠:2. Inclusion of sodium bicarbonate with polyethylene glycol:
1)加热熔融一定量的聚乙二醇,然后取等量的碳酸氢钠进行搅拌,并向碳酸氢钠中缓慢加入熔融的聚乙二醇进行包合,包合均匀后冷却至室温;1) Heat and melt a certain amount of polyethylene glycol, then take an equal amount of sodium bicarbonate for stirring, and slowly add molten polyethylene glycol to the sodium bicarbonate for clathrate, clathrate evenly and cool to room temperature;
2)将上述包合物研细后并过80目筛,得到碳酸氢钠包合物。2) Grind the above clathrate and pass through an 80-mesh sieve to obtain the clathrate of sodium bicarbonate.
3、填充剂中添加香精:3. Add flavor to filler:
1)取一定量的葡糖糖过80目筛,并与适量的桔子味香精混合后制成颗粒;1) Take a certain amount of glucose and pass it through an 80-mesh sieve, and mix it with an appropriate amount of orange flavor essence to make granules;
2)将上述颗粒过80目筛,然后在40℃以上的环境中干燥2h以上;2) Pass the above granules through an 80-mesh sieve, and then dry them in an environment above 40°C for more than 2 hours;
3)将上述颗粒研细后过80目筛。3) Grind the above particles finely and pass through an 80-mesh sieve.
4、将微晶纤维素、硬脂酸镁、抗坏血酸、枸橼酸、氯化钠过80目筛。4. Pass microcrystalline cellulose, magnesium stearate, ascorbic acid, citric acid and sodium chloride through an 80-mesh sieve.
第二步、取甘草酸二铵脂质复合物33.6份、抗坏血酸15份、矫味剂129份、枸橼酸33.75份、碳酸氢钠包合物52.5份以及氯化钠30份,均匀混合形成甘草酸二铵脂质复合物混合物;The second step, take 33.6 parts of diammonium glycyrrhizinate lipid complex, 15 parts of ascorbic acid, 129 parts of flavoring agent, 33.75 parts of citric acid, 52.5 parts of sodium bicarbonate clathrate and 30 parts of sodium chloride, and mix evenly to form Diammonium Glycyrrhizinate Lipid Complex Mixture;
第三步、通过湿法制粒将甘草酸二铵脂质复合物混合物制成甘草酸二铵脂质复合物泡腾颗粒;湿法制粒分以下步骤:In the third step, the diammonium glycyrrhizinate lipid complex mixture is made into diammonium glycyrrhizinate lipid complex effervescent granules by wet granulation; the wet granulation is divided into the following steps:
1、将甘草酸二铵脂质复合物混合物加入无水乙醇中制成软材,然后过16目筛制成湿颗粒,并在40℃以上的环境中干燥2h以上;1. Add diammonium glycyrrhizinate lipid complex mixture into absolute ethanol to make soft material, then pass through a 16-mesh sieve to make wet granules, and dry in an environment above 40°C for more than 2 hours;
2、将上述颗粒过16目筛,然后加入6份微晶纤维素和0.15份硬脂酸镁后混合均匀,并在40℃的真空环境下干燥2.5h;2. Pass the above granules through a 16-mesh sieve, then add 6 parts of microcrystalline cellulose and 0.15 parts of magnesium stearate, mix well, and dry at 40°C for 2.5 hours in a vacuum environment;
3、将上述颗粒过16目筛,得到甘草酸二铵脂质复合物泡腾颗粒。3. Pass the above granules through a 16-mesh sieve to obtain diammonium glycyrrhizinate lipid complex effervescent granules.
实施例三:Embodiment three:
第一步、原料的预处理:The first step, pretreatment of raw materials:
1、将甘草酸二铵制成甘草酸二铵脂质复合物;1, diammonium glycyrrhizinate is made into diammonium glycyrrhizinate lipid complex;
1)将甘草酸二铵制成甘草酸二铵提纯物:1) Diammonium glycyrrhizinate is made into diammonium glycyrrhizinate extract:
①向容器中加入100份甘草酸二铵和900份乙醇水溶液(纯度为80-85%),并在105℃的水浴中加热至溶解状态;①Add 100 parts of diammonium glycyrrhizinate and 900 parts of ethanol aqueous solution (80-85% purity) into the container, and heat it in a water bath at 105°C until it dissolves;
②将上述溶液静置片刻,然后倾取上清液至另一容器中冷却静置14h,通过抽滤得到结晶体;②Let the above solution stand for a while, then pour the supernatant into another container to cool and stand for 14 hours, and obtain crystals by suction filtration;
③向容器中加入上述结晶体和700份乙醇水溶液(纯度为80-85%),在105℃的水浴加热至溶解状态;③Add the above crystals and 700 parts of ethanol aqueous solution (80-85% purity) into the container, and heat in a water bath at 105°C until dissolved;
④重复步骤②,然后将结晶体晾至无乙醇味状态;④Repeat step ②, and then dry the crystals to a state without ethanol smell;
⑤将上述结晶体在55℃以上的环境中干燥24h以上,得到含量为97.3%的甘草酸二铵提纯物。⑤ Dry the above-mentioned crystals in an environment above 55°C for more than 24 hours to obtain a purified diammonium glycyrrhizinate with a content of 97.3%.
2)将甘草酸二铵提纯物制成甘草酸二铵脂质复合物:2) Make diammonium glycyrrhizinate lipid complex from diammonium glycyrrhizinate extract:
①在容器中放入12份大豆磷脂和500份四氢呋喃,然后在74℃的水浴中通过磁力搅拌进行回流溶解,得到大豆磷脂四氢呋喃溶液;①Put 12 parts of soybean lecithin and 500 parts of tetrahydrofuran in a container, and then reflux and dissolve in a water bath at 74°C by magnetic stirring to obtain a solution of soybean lecithin in tetrahydrofuran;
②称取12份甘草酸二铵提纯物,然后倒入冷却后的大豆磷脂四氢呋喃溶液中,轻轻摇动后在74℃的水浴中通过磁力搅拌4h以上进行回流溶解,当溶液澄明后取出静置;② Weigh 12 parts of the purified diammonium glycyrrhizinate, then pour it into the cooled soybean lecithin tetrahydrofuran solution, shake it gently, and then reflux and dissolve it in a water bath at 74°C by magnetic stirring for more than 4 hours. When the solution is clear, take it out and let it stand ;
③将上述溶液倾出上清液至另一容器中,旋转蒸发直至无四氢呋喃味,然后研细并过80目筛,得到含量为45-48%的甘草酸二铵脂质复合物。③Pour the above solution into another container and pour the supernatant into another container, and evaporate until there is no tetrahydrofuran smell, then grind it finely and pass it through an 80-mesh sieve to obtain diammonium glycyrrhizinate lipid complex with a content of 45-48%.
2、用聚二乙醇包合碳酸氢钠:2. Inclusion of sodium bicarbonate with polyethylene glycol:
1)加热熔融一定量的聚乙二醇,然后取等量的碳酸氢钠进行搅拌,并向碳酸氢钠中缓慢加入熔融的聚乙二醇进行包合,包合均匀后冷却至室温;1) Heat and melt a certain amount of polyethylene glycol, then take an equal amount of sodium bicarbonate for stirring, and slowly add molten polyethylene glycol to the sodium bicarbonate for clathrate, clathrate evenly and cool to room temperature;
2)将上述包合物研细后并过80目筛,得到碳酸氢钠包合物。2) Grind the above clathrate and pass through an 80-mesh sieve to obtain the clathrate of sodium bicarbonate.
3、填充剂中添加香精:3. Add flavor to filler:
1)取一定量的甘露醇过80目筛,并与适量的草莓味香精混合后制成颗粒;1) Take a certain amount of mannitol and pass it through an 80-mesh sieve, and mix it with an appropriate amount of strawberry flavor essence to make granules;
2)将上述颗粒过80目筛,然后在43℃以上的环境中干燥2h以上;2) Pass the above granules through an 80-mesh sieve, and then dry them in an environment above 43°C for more than 2 hours;
3)将上述颗粒研细后过80目筛。3) Grind the above particles finely and pass through an 80-mesh sieve.
4、将微晶纤维素、硬脂酸镁、抗坏血酸、枸橼酸、氯化钠过80目筛。4. Pass microcrystalline cellulose, magnesium stearate, ascorbic acid, citric acid and sodium chloride through an 80-mesh sieve.
第二步、取甘草酸二铵脂质复合物35份、抗坏血酸18份、矫味剂132份、枸橼酸35份、碳酸氢钠包合物55份以及氯化钠32份,均匀混合形成甘草酸二铵脂质复合物混合物;The second step, take 35 parts of diammonium glycyrrhizinate lipid complex, 18 parts of ascorbic acid, 132 parts of flavoring agent, 35 parts of citric acid, 55 parts of sodium bicarbonate clathrate and 32 parts of sodium chloride, and mix evenly to form Diammonium Glycyrrhizinate Lipid Complex Mixture;
第三步、通过湿法制粒将甘草酸二铵混合物制成甘草酸二铵脂质复合物泡腾颗粒;湿法制粒分以下步骤:In the third step, the diammonium glycyrrhizinate mixture is made into diammonium glycyrrhizinate lipid complex effervescent granules by wet granulation; the wet granulation is divided into the following steps:
1、将甘草酸二铵脂质复合物混合物加入无水乙醇中制成软材,然后过16目筛制成湿颗粒,并在43℃以上的环境中干燥2h以上;1. Add diammonium glycyrrhizinate lipid complex mixture into absolute ethanol to make a soft material, then pass through a 16-mesh sieve to make wet granules, and dry in an environment above 43°C for more than 2 hours;
2、将上述颗粒过16目筛,然后加入6份微晶纤维素和0.15份硬脂酸镁后混合均匀,并在43℃的真空环境下干燥3h;2. Pass the above granules through a 16-mesh sieve, then add 6 parts of microcrystalline cellulose and 0.15 parts of magnesium stearate, mix well, and dry at 43°C for 3 hours in a vacuum environment;
3、将上述颗粒过16目筛,得到甘草酸二铵脂质复合物泡腾颗粒。3. Pass the above granules through a 16-mesh sieve to obtain diammonium glycyrrhizinate lipid complex effervescent granules.
泡腾剂(包括泡腾颗粒)与普通片剂(肠溶片、肠溶胶囊和胶囊剂)的不同之处在于,泡腾剂中含有泡腾崩解剂;当泡腾剂放入水中时,在泡腾崩解剂的作用下,即刻会产生大量气泡(二氧化碳),可促使泡腾剂在水中上下翻滚达到迅速崩解和融化的效果,并且二氧化碳部分溶解于水中后,还能使水中带有类似汽水的口感;因此,将甘草酸二铵脂质复合物制成泡腾颗粒进行服用,具有崩解快速、口味俱佳、服用方便(适合儿童、老年人等服药困难人员服用)、起效迅速、疗效显著等特点。The difference between effervescent agents (including effervescent granules) and ordinary tablets (enteric-coated tablets, enteric-coated capsules, and capsules) is that effervescent agents contain effervescent disintegrants; , under the action of the effervescent disintegrating agent, a large number of bubbles (carbon dioxide) will be generated immediately, which can promote the effervescent agent to roll up and down in the water to achieve the effect of rapid disintegration and melting, and after the carbon dioxide is partially dissolved in the water, it can also make the water It has a mouthfeel similar to that of soda; therefore, the diammonium glycyrrhizinate lipid complex is made into effervescent granules for taking, which has the advantages of rapid disintegration, good taste, and convenient administration (suitable for children, the elderly and other people who have difficulty taking medicine), It has the characteristics of rapid onset and remarkable curative effect.
本发明的实验数据如下:The experimental data of the present invention are as follows:
在进行甘草酸二铵脂质复合物泡腾颗粒与甘草酸二铵胶囊对急性肝脏损害保护作用的对比实验时,采用小鼠腹腔注射四氯化碳复制急性肝脏损害模型,用来测定血清ALT、AST并对肝脏进行病理学观察。In the comparative experiment of diammonium glycyrrhizinate lipoplex effervescent granules and diammonium glycyrrhizinate capsules on acute liver damage, mice were injected intraperitoneally with carbon tetrachloride to reproduce the acute liver damage model and used to measure serum ALT , AST and pathological observation of the liver.
结果显示:与甘草酸二铵胶囊相比,甘草酸二铵脂质复合物泡腾颗粒能较好地降低急性肝损小鼠的ALT水平(P<0.01),小鼠肝组织评分结果显示脂质复合物泡腾颗粒能显著降低四氯化碳染毒肝脏组织的病理评分(P<0.01)。The results showed that compared with Diammonium Glycyrrhizinate Capsules, Diammonium Glycyrrhizinate Lipid Complex Effervescent Granules could better reduce the ALT level in mice with acute liver injury (P<0.01). The effervescent granule of substance complex can significantly reduce the pathological score of carbon tetrachloride-infected liver tissue (P<0.01).
甘草酸二铵脂质复合物泡腾颗粒组的血药浓度和肝组织浓度分别约为甘草酸二铵胶囊组的2倍和26倍;在组内比较中,甘草酸二铵脂质复合物泡腾颗粒组的肝组织浓度约为血药浓度的13-14倍,甘草酸二铵胶囊组的血药浓度和肝组织浓度基本相同。The blood drug concentration and liver tissue concentration of the diammonium glycyrrhizinate lipoplex effervescent granule group were about 2 times and 26 times that of the diammonium glycyrrhizinate capsule group; The liver tissue concentration of the effervescent granule group is about 13-14 times of the blood concentration, and the blood concentration of the diammonium glycyrrhizinate capsule group is basically the same as the liver tissue concentration.
因此,甘草酸二铵脂质复合物泡腾颗粒能显著提高小鼠体内的药物浓度,并能把药物有效富集到肝组织中,起到了靶向作用,对于小鼠急性化学性肝损伤具有更好的保护作用;由此可知,甘草酸二铵脂质复合物泡腾颗粒能有效提升药物吸收效果和生物利用度,以达到保护肝细胞膜和改善肝功能的效果,疗效显著。Therefore, diammonium glycyrrhizinate lipid complex effervescent granules can significantly increase the drug concentration in mice, and can effectively enrich the drug into the liver tissue, playing a targeting role, and has a certain effect on acute chemical liver injury in mice. Better protective effect; thus, diammonium glycyrrhizinate lipid complex effervescent granules can effectively improve drug absorption and bioavailability, so as to achieve the effect of protecting liver cell membrane and improving liver function, and the curative effect is remarkable.
本文中所述的“份”均为重量份。The "parts" described herein are all parts by weight.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013102764710A CN103330684A (en) | 2013-07-01 | 2013-07-01 | Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013102764710A CN103330684A (en) | 2013-07-01 | 2013-07-01 | Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103330684A true CN103330684A (en) | 2013-10-02 |
Family
ID=49238937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013102764710A Pending CN103330684A (en) | 2013-07-01 | 2013-07-01 | Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103330684A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045934A1 (en) * | 1998-03-11 | 1999-09-16 | Grelan Pharmaceutical Co., Ltd. | Bubbling enteric coated preparations |
CN1594332A (en) * | 2004-06-23 | 2005-03-16 | 江苏正大天晴药业股份有限公司 | Glycyrrhetic acid and phospholipid composites of glycyrrhetate and process for preparing same |
CN1709343A (en) * | 2005-06-22 | 2005-12-21 | 肖春 | Medicinal composition for protecting liver, and its formulation preparing method |
CN1903184A (en) * | 2006-08-08 | 2007-01-31 | 阿尔贝拉医药(中国)有限公司 | Effervesce tablets for treating liver diseases |
CN101633683A (en) * | 2008-07-26 | 2010-01-27 | 刘力 | Antihepatitis medicament, preparation method thereof and use thereof |
CN101914126A (en) * | 2009-10-22 | 2010-12-15 | 北京协和药厂 | Preparation method of diammonium glycyrrhizinate salt capable of accurately controlling ammonium radical content |
-
2013
- 2013-07-01 CN CN2013102764710A patent/CN103330684A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045934A1 (en) * | 1998-03-11 | 1999-09-16 | Grelan Pharmaceutical Co., Ltd. | Bubbling enteric coated preparations |
CN1594332A (en) * | 2004-06-23 | 2005-03-16 | 江苏正大天晴药业股份有限公司 | Glycyrrhetic acid and phospholipid composites of glycyrrhetate and process for preparing same |
CN1709343A (en) * | 2005-06-22 | 2005-12-21 | 肖春 | Medicinal composition for protecting liver, and its formulation preparing method |
CN1903184A (en) * | 2006-08-08 | 2007-01-31 | 阿尔贝拉医药(中国)有限公司 | Effervesce tablets for treating liver diseases |
CN101633683A (en) * | 2008-07-26 | 2010-01-27 | 刘力 | Antihepatitis medicament, preparation method thereof and use thereof |
CN101914126A (en) * | 2009-10-22 | 2010-12-15 | 北京协和药厂 | Preparation method of diammonium glycyrrhizinate salt capable of accurately controlling ammonium radical content |
Non-Patent Citations (2)
Title |
---|
李松龙等: "甘草酸二铵泡腾颗粒在兔体内的药动学", 《中国医药工业杂志》 * |
王淑华等: "泡腾片的常用辅料及制备方法", 《食品与药品》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103159769B (en) | Doxofylline compound and medicine composition thereof | |
CN102579378B (en) | Child cefdinir composition freeze-dried oral disintegrating tablet and preparation method thereof | |
CN102631336B (en) | Freeze-drying orally disintegrating tablet with vitamin K1 composition for infants and preparation method for freeze-drying orally disintegrating tablet | |
CN103893139A (en) | Asenapine composition and preparation method thereof | |
CN112972404A (en) | Sildenafil freeze-dried orally disintegrating tablet and preparation method thereof | |
CN102600119B (en) | Pediatric acetaminophen composition | |
CN104415097A (en) | Sublingual administration preparation containing total alkaloids in lotus leaf or lotus plumule, and use thereof | |
CN103860517A (en) | Ornithine aspartate effervescent tablets and preparing process thereof | |
CN103330684A (en) | Preparation method of diammonium glycyrrhizinate lipid compound effervescent granule | |
US20200261362A1 (en) | Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor | |
CN102772383A (en) | Azithromycin composition freeze-dried orally disintegrating tablet and preparation method thereof | |
CN102772454A (en) | Brucea javanica oil dry emulsion capsule and preparation method thereof | |
CN107759654B (en) | Application of Astragalic Acid and Its Derivatives in the Preparation of Antithrombotic Drugs | |
CN102688191B (en) | Medicine composition containing vitamin K1 and oil | |
CN102614212B (en) | Freeze-dried orally disintegrating tablets of pediatric ribavirin composition, and preparation method thereof | |
CN103721267A (en) | Composition containing desloratadine citrate disodium | |
CN102525979B (en) | Infant ibuprofen composition | |
CN102600153B (en) | Pediatric compound anisodamine hydrobromide and chlorpheniramine maleate freeze-dried orally disintegrating tablets and manufacturing method thereof | |
CN102525980B (en) | Children cetirizine hydrochloride composition | |
CN101301304A (en) | A traditional Chinese medicine combination for treating ischemic stroke and its preparation method | |
CN103877231B (en) | A kind of seven tastes nourish heart the preparation method of spleen-invigorating granula | |
CN116019773A (en) | A kind of amlodipine besylate freeze-dried orally disintegrating tablet and preparation method thereof | |
CN104644809A (en) | TGCJ sustained-release tablet and preparation method thereof | |
CN103720665A (en) | Desloratadine citrate disodium composition for injection | |
CN100438888C (en) | Freeze-dried preparation containing honeysuckle extract and scutellaria baicalensis extract and its manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131002 |